{"id":"W4321612529","doi":"10.1001/jamaoncol.2022.7770","title":"Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval","year":2023,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health; Astellas Pharma; Seagen; Flatiron Health; Emerson Collective; National Palliative Care Research Center; Eisai; National Comprehensive Cancer Network; F. Hoffmann-La Roche; University of Pennsylvania; Myriad Genetics; Prostate Cancer Foundation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Cancer Care Ontario; Pfizer; Amgen; Conquer Cancer Foundation","keywords":"Medicine; Food and drug administration; Cancer drugs; Drug approval; Drug; Drug administration; Administration (probate law); Cancer; Pharmacology; Intensive care medicine; Oncology; Family medicine; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002712221,0.0001762284,0.0004045056,0.0009229532,0.0002884241,0.0008292024,0.0002941949,0.0005934018,0.003819353],"category_scores_gemma":[0.01811374,0.00019035,0.001022022,0.001188503,0.000260828,0.000628819,0.0004948164,0.001190034,0.0003927813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007250074,"about_ca_system_score_gemma":0.0006534811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006307607,"about_ca_topic_score_gemma":0.003933079,"domain_scores_codex":[0.9975957,0.001033243,0.0003862034,0.000324825,0.0004503118,0.0002095463],"domain_scores_gemma":[0.97212,0.007628099,0.01686876,0.001137835,0.00130379,0.0009414545],"domain_codex":null,"domain_gemma":"evaluation","domain_candidate":"evaluation","domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001168956,0.0002652676,0.9917682,0.00005627529,0.0005692245,0.00004824295,0.0000430476,0.0002899487,0.00009147554,0.000191138,0.0008170391,0.004691053],"study_design_scores_gemma":[0.0000593225,0.001170058,0.996055,0.00003638284,0.0002356827,0.0002771335,0.00008637648,0.0004017462,0.0001480922,0.0001233257,0.001393092,0.00001379428],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895821,0.001650423,0.0003459357,0.0004589757,0.0000303311,0.00007916556,0.004963479,0.00001332146,0.002876421],"genre_scores_gemma":[0.9957568,0.0004707894,0.000123621,0.0003282256,0.00004172609,0.0000375955,0.002662527,0.000004731553,0.000573953],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9972878,"threshold_uncertainty_score":0.01434374,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2842487831802643,"score_gpt":0.43793605879495,"score_spread":0.1536872756146857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}